EUVIMEDEUVIMED entdecken
Crossref

Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention

K Sruthi, S L Manju iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von K Sruthi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, India. Hauptthemen laut MEDLINE: alpha-Amylases, Diabetes Mellitus, Type 2, Glycoside Hydrolase Inhibitors, alpha-Glucosidases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: This study was supported by VIT SEED GRANT (RGEMS, SG20240009)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of fifteen 1,2,3‐triazole derivatives 6(a–o) were developed and evaluated for their inhibitory effects on carbohydrate‐hydrolyzing enzymes implicated in Type 2 diabetes management. The compounds were assessed through in silico studies (including molecular docking and ADME predictions) and in vitro assays such as α‐amylase, α‐glucosidase, and antioxidant activities. Notably, the compounds 6a , 6d , 6g , 6h , 6k , 6l , and 6n exhibited dual inhibition against both enzymes. Among them, compound 6a exhibited the most potent α‐glucosidase inhibition (IC 50 = 22.15 ± 0.75 µM), comparable to the reference drug acarbose (IC 50 = 21.07 ± 0.05 µM). Meanwhile, compound 6h demonstrated strong α‐amylase inhibition (IC 50 = 84.46 ± 1.14 µM) compared with standard acarbose (IC 50 = 87.62 ± 0.47 µM). Cytotoxicity studies of the most active compounds 6a and 6h indicated moderate cytotoxicity, with IC 50 values of 32.87 ± 1.2 µM and 32.42 ± 1.5 µM, respectively, suggesting a reasonable safety margin compatible with continued drug development. The DPPH assay revealed moderate to good activity for all compounds 6(a–o) , with IC 50 values ranging from 39.60 ± 0.15 to 99.45 ± 0.12 µM. These findings support the therapeutic potential of these compounds as antidiabetic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-AmylasesDiabetes Mellitus, Type 2Glycoside Hydrolase Inhibitorsalpha-GlucosidasesTriazolesHypoglycemic AgentsStructure-Activity RelationshipHumansMolecular Docking SimulationMolecular StructureDose-Response Relationship, DrugAntioxidantsInhibitory Concentration 50Drug Development

Stichwörter der Autor:innen

1,2,3‐triazoleADMEMTT assayantioxidantmolecular dockingα‐glucosidase and α‐amylase inhibition

Substanzen

alpha-AmylasesGlycoside Hydrolase Inhibitorsalpha-GlucosidasesTriazolesHypoglycemic AgentsAntioxidants

Autor:innen und Institutionen

  • Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, India.

ORCID-Profile: S L Manju

Förderung

  • This study was supported by VIT SEED GRANT (RGEMS, SG20240009).

Zitieren

APA

Sruthi, K., & Manju, S. L. (2025). Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70088

Vancouver

Sruthi K, Manju SL. Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70088

BibTeX
@article{Sruthi2025,
  author = {Sruthi, K and Manju, S L},
  title = {Development of 1,2,3‐Triazoles as Dual Enzyme Inhibitors Targeting α‐Amylase and α‐Glucosidase for Type 2 Diabetes Intervention},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70088}
}
Kostenlos starten →